Becton, Dickinson and Company $BDX Shares Acquired by Brighton Jones LLC

Brighton Jones LLC lifted its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 257.4% in the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 6,737 shares of the medical instruments supplier’s stock after acquiring an additional 4,852 shares during the period. Brighton Jones LLC’s holdings in Becton, Dickinson and Company were worth $1,160,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Graybill Wealth Management LTD. increased its position in shares of Becton, Dickinson and Company by 1.5% during the 2nd quarter. Graybill Wealth Management LTD. now owns 18,733 shares of the medical instruments supplier’s stock valued at $3,227,000 after purchasing an additional 281 shares during the period. CVA Family Office LLC lifted its position in shares of Becton, Dickinson and Company by 79.5% during the 2nd quarter. CVA Family Office LLC now owns 219 shares of the medical instruments supplier’s stock valued at $38,000 after acquiring an additional 97 shares during the last quarter. AG2R LA Mondiale Gestion D Actifs raised its stake in Becton, Dickinson and Company by 8.3% during the 2nd quarter. AG2R LA Mondiale Gestion D Actifs now owns 12,105 shares of the medical instruments supplier’s stock valued at $2,085,000 after purchasing an additional 924 shares during the period. Focus Partners Advisor Solutions LLC raised its stake in Becton, Dickinson and Company by 42.3% during the 2nd quarter. Focus Partners Advisor Solutions LLC now owns 4,500 shares of the medical instruments supplier’s stock valued at $775,000 after purchasing an additional 1,337 shares during the period. Finally, PKO Investment Management Joint Stock Co raised its stake in Becton, Dickinson and Company by 18.5% during the 2nd quarter. PKO Investment Management Joint Stock Co now owns 7,700 shares of the medical instruments supplier’s stock valued at $1,326,000 after purchasing an additional 1,200 shares during the period. 86.97% of the stock is owned by institutional investors.

Becton, Dickinson and Company Stock Performance

NYSE:BDX opened at $187.02 on Tuesday. Becton, Dickinson and Company has a 1 year low of $163.33 and a 1 year high of $251.99. The firm has a 50 day moving average of $189.76 and a 200-day moving average of $183.63. The company has a current ratio of 1.10, a quick ratio of 0.62 and a debt-to-equity ratio of 0.69. The stock has a market capitalization of $53.61 billion, a P/E ratio of 33.64, a price-to-earnings-growth ratio of 1.45 and a beta of 0.25.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share (EPS) for the quarter. The company had revenue of $5.32 billion during the quarter. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. As a group, sell-side analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Insider Buying and Selling at Becton, Dickinson and Company

In related news, Director Claire Fraser sold 917 shares of the firm’s stock in a transaction that occurred on Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total value of $171,937.50. Following the completion of the sale, the director owned 22,226 shares of the company’s stock, valued at $4,167,375. This trade represents a 3.96% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders have sold a total of 1,838 shares of company stock valued at $348,392 over the last three months. Company insiders own 0.36% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on BDX shares. Wall Street Zen raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Saturday, August 9th. Piper Sandler reissued a “neutral” rating and set a $200.00 target price (up from $185.00) on shares of Becton, Dickinson and Company in a research report on Friday, August 8th. Weiss Ratings restated a “hold (c-)” rating on shares of Becton, Dickinson and Company in a report on Wednesday, October 8th. Morgan Stanley upped their price target on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an “overweight” rating in a report on Monday, August 11th. Finally, Royal Bank Of Canada reissued a “sector perform” rating and set a $211.00 target price on shares of Becton, Dickinson and Company in a research report on Thursday, October 16th. Three investment analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $205.40.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.